NEW YORK, December 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), WellPoint Inc. (NYSE: WLP), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), CareFusion Corporation (NYSE: CFN), and Hologic Inc. (NASDAQ: HOLX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Baxter International Inc. Research Report
On December 2, 2013, Baxter International Inc. (Baxter), along with Halozyme Therapeutics, Inc. (Halozyme), announced that Baxter has completed submission of an amended biologics license application (BLA) to the US Food and Drug Administration (FDA) for re-initiating the review process for approval of HyQvia (Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase) facilitated subcutaneous infusion for the treatment of adults patients with primary immunodeficiency (PI). Baxter stated that the Company and Halozyme submitted additional preclinical data that was requested from the FDA in 2012, and are expecting a six-month review period. Commenting on the release, Ludwig Hantson, Ph.D., President of Baxter's BioScience business, stated, "We believe that if approved, HyQvia may become a valuable option for patients with immune deficiency as it allows for the delivery of a full dose of immunoglobulin often in a single site every three to four weeks, in the comfort of a patient's home." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
WellPoint Inc. Research Report
WellPoint Inc. (WellPoint) posted under "Events & Webcasts" in the Investors section of its website that the Company will participate in the JPMorgan Healthcare Conference on January 14, 2014 at 9:30 a.m. PT in San Francisco, California, US. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Questcor Pharmaceuticals, Inc. Research Report
On December 2, 2013, Questcor Pharmaceuticals, Inc.'s (Questcor Pharmaceuticals) stock closed at $58.75, an increase of 1.28%. Over the past three trading days, the Company's stock went up by 3.93% compared to the Dow Jones Industrial Average which went down by 0.40% during the same trading period. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
CareFusion Corporation Research Report
On December 2, 2013, CareFusion Corporation's (CareFusion) stock went up by 0.65% as it closed the day at $40.11. The Company's stock went up by 0.85% over the previous three trading sessions, compared to the S&P 500 which declined 0.10% during the same trading period. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Hologic Inc. Research Report
On December 2, 2013, Hologic Inc.'s (Hologic) stock declined by 0.36% and closed the day at $22.31. Over the previous three trading days, the Company's stock went down by 1.24% compared to the Nasdaq Composite which went up by 0.68% during the same trading period. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved